Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

hospira, inc. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. risk summary the 10 ml cisatracurium besylate injection multiple-dose vials contain the preservative benzyl alcohol. therefore, if cisatracurium besylate injection is needed during pregnancy, consider using a benzyl alcohol-free formulation (i.e., 5 ml and 20 ml cisatracurium besylate injection single-dose vials). because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely. however, adverse reactions have occurred in premature neonates and low birth weight infants who received intravenously administered benzyl alcohol-containing drugs [see contraindications (4), warnings and precautions (5.2), and use in specific populations (8.4)] . there are no available clinical trial data on cisatracurium use in pregnancy to evaluate a drug-associated risk of

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - cisatracurium besilate, quantity: 2.68 mg/ml - injection, solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

sandoz inc - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. risk summary the 10 ml cisatracurium besylate multiple-dose vials contain the preservative benzyl alcohol. therefore, if cisatracurium besylate is needed during pregnancy, consider using a benzyl alcohol-free formulation (i.e., 5 ml and 20 ml cisatracurium besylate single-dose vials). because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely. however, adverse reactions have occurred in premature neonates and low birth weight infants who received intravenously administered benzyl alcohol-containing drugs [see contraindications (4), warnings and precautions (5.2), and use in specific populations (8.4)] . there are no available clinical trial data on cisatracurium use in pregnancy to evaluate a drug associated risk of major birth defects, miscarria

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

civica, inc. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. risk summary the 10 ml cisatracurium besylate multiple-dose vials contain the preservative benzyl alcohol. therefore, if cisatracurium besylate is needed during pregnancy, consider using a benzyl alcohol-free formulation (i.e., 5 ml and 20 ml cisatracurium besylate single-dose vials). because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely. however, adverse reactions have occurred in premature neonates and low birth weight infants who received intravenously administered benzyl alcohol-containing drugs [see contraindications (4), warnings and precautions (5.2), and use in specific populations (8.4)] . there are no available clinical trial data on cisatracurium use in pregnancy to evaluate a drug associated risk of major birth defects, miscarria

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

civica, inc. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. risk summary there are no available clinical trial data on cisatracurium use in pregnancy to evaluate a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal studies conducted in rats administered cisatracurium besylate during organogenesis (gestational day 6 to 15) found no evidence of fetal harm at 0.8 times (ventilated rats) the exposure from a human starting iv bolus dose of 0.2 mg/kg (see data) . the estimated background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, r

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - atracurium besilate, quantity: 10.5 mg/ml - injection, solution - excipient ingredients: water for injections; benzenesulfonic acid - indications for the united kingdom: atracurium besilate solution for injection is a medicine which acts as a muscle relaxant. atracurium besilate solution for injection is used during surgery to relax muscles and to assist with inserting a breathing tube and with artificial breathing. it is also used to help with artificial breathing in patients in intensive care. indications for france: the injection solution of atracurium is used during surgery to relax the muscles as well as to facilitate the intubation of the endotracheal and assisted ventilation. it is also used to allow artificial ventilation in patients in intensive care.

Belgia - inglise - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Belgia - inglise - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Belgia - inglise - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - cisatracurium besilate 6,7 mg/ml - eq. cisatracurium 5 mg/ml - solution for injection/infusion - 5 mg/ml - cisatracurium besilate 6.7 mg/ml - cisatracurium

Belgia - inglise - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium